67 reports

Gastric cancer

4546 5000 3864

However, gastric cancer survival rates still lag significantly behind many other highincidence cancers such as colorectal cancer, breast cancer, and prostate cancer (SEER, 2016).

  • Cancer
  • Asia
  • Japan
  • Eli Lilly & Co.
  • Merck & Co., Inc.

Head and neck cancer

4546 5000 3864

National Cancer Institute (2016) Head and Neck Cancer.

  • Cancer
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • Merck & Co., Inc.

Colorectal cancer

4546 5000 3864

National Cancer Institute (2014a) Colorectal cancer.

  • Cancer
  • Europe
  • Japan
  • World
  • Taiho Pharmaceutical Co., Ltd.

Pancreatic cancer

4546 5000 3864

Cancer Research UK (2016a) Pancreatic cancer symptoms.

  • Cancer
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • NewLink Genetics Corporation
  • Taiho Pharmaceutical Co., Ltd.

Cancer Research UK (2013) Cancer Drugs Fund.

  • Cancer
  • Europe
  • Japan
  • ArQule, Inc.
  • Eli Lilly & Co.

American Cancer Society (2015a) Cancer Facts & Figures.

  • Cancer
  • Europe
  • Japan
  • AstraZeneca PLC
  • TESARO, Inc.

National Cancer Center (2013) Cancer Statistics in Japan.

  • Cancer
  • Europe
  • Japan
  • GlaxoSmithKline plc
  • Roche Group

Renal cell cancer

4546 5000 3864

American Cancer Society (2016) Kidney Cancer ACS.

  • Cancer
  • Asia
  • Europe
  • Japan
  • World

Prostate cancer

4546 5000 3864

MD Anderson Cancer Center (2015) Prostate Cancer.

  • Cancer
  • Europe
  • Japan
  • World
  • PROVENGE group

Market Spotlight: Uterine Cancer KEY TAKEAWAYS DISEASE BACKGROUND TREATMENT Surgery Radiation therapy Chemotherapy Hormone therapy Palliative care EPIDEMIOLOGY PIPELINE DRUGS LICENSING AND ASSET ACQUISITION DEALS PARENT PATENTS CLINICAL TRIAL LANDSCAPE Sponsors by status Sponsors by phase B

  • Cancer
  • Clinical Trial
  • Pathology
  • Forecast

Market Spotlight: Thyroid Cancer CONTENTS ## KEY TAKEAWAYS ## DISEASE BACKGROUND ## Thyroid cancer subtypes ## TREATMENT ## Surgery ## Radioactive iodine (RAI) therapy ## Thyroid hormone therapy ## External-beam radiation therapy ## Targeted therapy ## EPIDEMIOLOGY ## MARKETED DRUGS ## PIPE

  • Cancer
  • Forecast

Market Spotlight: Cervical Cancer ## KEY TAKEAWAYS ## DISEASE BACKGROUND ## TREATMENT ## Surgery ## Radiotherapy ## Chemotherapy ## Targeted therapy ## EPIDEMIOLOGY ## MARKETED DRUGS ## Approvals by country ## PIPELINE DRUGS ## KEY UPCOMING EVENTS ## LICENSING AND ASSET ACQUISITION DEALS ## Alligat

  • Cancer
  • Cervical Cancer
  • Pathology
  • Forecast

Gastric Cancer Forecast and Market Analysis to 2024 FORECAST: GASTRIC CANCER (Published on ## December 2017) EXECUTIVE SUMMARY RECENT FORECAST UPDATES MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHODOLOGY BIBLIOGRAPHY PRODUCT PROF

  • Cancer
  • Gastric Cancer
  • Pathology
  • Europe
  • Japan

Colorectal Cancer Forecast and Market Analysis to 2036 FORECAST: COLORECTAL CANCER IN THE US, JAPAN, AND ##EU (Published on ## December 2017) EXECUTIVE SUMMARY RECENT FORECAST UPDATES MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHO

  • Cancer
  • Colorectal Cancer
  • Europe
  • Japan
  • Demand

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024 FORECAST: PROSTATE CANCER (Published on ## January 2018) EXECUTIVE SUMMARY MARKET DYNAMICS FORECAST AND FUTURE TRENDS MARKET DEFINITION AND METHODOLOGY PRIMARY RESEARCH METHODOLOGY BIBLIOGRAPHY PRODUCT PROFILE (L

  • Cancer
  • Prostate Cancer
  • Europe
  • Japan
  • Demand

Human papillomavirus (HPV) is a major cause of the main types of cervical cancer (the two main histological subtypes being squamous cell cancer and adenocarcinoma), and is believed to be responsible for around ##% of cervical cancers.

  • Cancer
  • Cervical Cancer
  • Pathology
  • Europe
  • Japan

Renal cell cancer (RCC) disease forecast and market analysis to 2035 CONTENTS (Full Disease Coverage) ## FORECAST: RENAL CELL CANCER ## Executive Summary ## Market Overview and Trends ## Methodology and Market Definition ## Afinitor (everolimus) ## AGS-## ## atezolizumab ## Avas

  • Cancer
  • Renal Cancer
  • Europe
  • Japan
  • Demand

More than ##% of lung cancers are non-small cell lung cancers (NSCLC), with the exact proportion depending on the country in question.

  • Cancer
  • Lung Cancer
  • Europe
  • Japan
  • Demand

AMERICAN CANCER SOCIETY (2016) PROSTATE CANCER.

  • Cancer
  • Tuberculosis
  • Europe
  • Spain
  • United States

In order to accurately size the at-risk population, Datamonitor Healthcare identified key cancers to include in this analysis; the eight cancers selected were bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck

  • Cancer
  • Europe
  • Japan
  • Amgen Inc.
  • Galenica Group

Drug Analysis: Rubraca

9091 10000 7727

Drug Analysis: Rubraca Product Profiles Rubraca : Prostate cancer Rubraca : Ovarian cancer LIST OF FIGURES Figure ##: Rubraca for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate cancer Figure ##: Da

  • Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Europe
  • United States

Drug analysis: Vectibix Product Profiles Vectibix : Colorectal cancer (CRC) LIST OF FIGURES Figure ##: Vectibix for colorectal cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Vectibix for colorectal cancer Figure ##: Datamonitor Healthca

  • Cancer
  • Colorectal Cancer
  • Therapy
  • Europe
  • Japan

Drug Analysis: DCVAC/ PCa Product Profiles DCVAC/ PCa : Prostate cancer LIST OF FIGURES Figure ##: DCVAC/ PCa for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of DCVAC/ PCa for prostate cancer Figure ##: Datamoni

  • Biological Therapy
  • Cancer
  • Cell Therapy
  • Europe
  • Japan

Drug Analysis: Jevtana

9091 10000 7727

Drug Analysis: Jevtana Product Profiles Jevtana : Prostate cancer LIST OF FIGURES Figure ##: Jevtana for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Jevtana for prostate cancer Figure ##: Datamonitor Healthcare’s drug assess

  • Cancer
  • Prostate Cancer
  • Therapy
  • Europe
  • Japan

Drug Analysis: Zytiga

9091 10000 7727

Drug Analysis: Zytiga Product Profiles Zytiga : Prostate cancer LIST OF FIGURES Figure ##: Zytiga for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Zytiga for prostate cancer Figure ##: Datamonitor Healthcare’s drug assessment

  • Cancer
  • Hormone
  • Therapy
  • Europe
  • Japan

Drug Analysis: darolutamide Product Profiles darolutamide : Prostate cancer LIST OF FIGURES Figure ##: Darolutamide for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of darolutamide for prostate cancer Figure ##: Datamonitor Heal

  • Cancer
  • Pathology
  • Prostate Cancer
  • Europe
  • Japan

Drug Analysis: Xtandi

9091 10000 7727

Drug Analysis: Xtandi Product Profiles Xtandi : Prostate cancer LIST OF FIGURES Figure ##: Xtandi for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Xtandi for prostate cancer Figure ##: Datamonitor Healthcare’s drug assessment

  • Cancer
  • Prostate Cancer
  • Europe
  • Japan

Drug Analysis: Xofigo

9091 10000 7727

Drug Analysis: Xofigo Product Profiles Xofigo : Prostate cancer LIST OF FIGURES Figure ##: Xofigo for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Xofigo for prostate cancer Figure ##: Datamonitor Healthcare’s drug assessment

  • Cancer
  • Prostate Cancer
  • Europe
  • Japan

Drug analysis: Lonsurf

9091 10000 7727

Drug analysis: Lonsurf Product Profiles Lonsurf : Colorectal cancer (CRC) LIST OF FIGURES Figure ##: Lonsurf for colorectal cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Lonsurf for colorectal cancer Figure ##: Datamonitor Healthcare’s

  • Cancer
  • Colorectal Cancer
  • Pathology
  • Europe
  • Japan

Drug Analysis: ipatasertib Product Profiles ipatasertib : Prostate cancer LIST OF FIGURES Figure ##: Ipatasertib for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of ipatasertib for prostate cancer Figure ##: Datamonitor Healthca

  • Cancer
  • Pathology
  • Prostate Cancer
  • Europe
  • Japan